169 related articles for article (PubMed ID: 38195076)
1. Case report: durable response of gliomatosis cerebri with concurrent tumor-treating fields (TTFields) and chemoradiotherapy treatment.
DesJarlais AM; Miller R; Ali AS; Niazi MZ; Cappelli L; Glass J; Farrell CJ; Shi W
Chin Clin Oncol; 2023 Dec; 12(6):69. PubMed ID: 38195076
[TBL] [Abstract][Full Text] [Related]
2. Concurrent chemoradiation and Tumor Treating Fields (TTFields, 200 kHz) for patients with newly diagnosed glioblastoma: patterns of progression in a single institution pilot study.
Ali AS; Lombardo J; Niazi MZ; Miller RC; Alnahhas I; Martinez NL; Andrews DW; Judy KD; Shi W
J Neurooncol; 2022 Nov; 160(2):345-350. PubMed ID: 36355259
[TBL] [Abstract][Full Text] [Related]
3. Initial experience with scalp sparing radiation with concurrent temozolomide and tumor treatment fields (SPARE) for patients with newly diagnosed glioblastoma.
Song A; Bar-Ad V; Martinez N; Glass J; Andrews DW; Judy K; Evans JJ; Farrell CJ; Werner-Wasik M; Chervoneva I; Ly M; Palmer JD; Liu H; Shi W
J Neurooncol; 2020 May; 147(3):653-661. PubMed ID: 32206976
[TBL] [Abstract][Full Text] [Related]
4. Scalp-Sparing Radiation With Concurrent Temozolomide and Tumor Treating Fields (SPARE) for Patients With Newly Diagnosed Glioblastoma.
Miller R; Song A; Ali A; Niazi M; Bar-Ad V; Martinez N; Glass J; Alnahhas I; Andrews D; Judy K; Evans J; Farrell C; Werner-Wasik M; Chervoneva I; Ly M; Palmer J; Liu H; Shi W
Front Oncol; 2022; 12():896246. PubMed ID: 35574391
[TBL] [Abstract][Full Text] [Related]
5. The Evolving Role of Tumor Treating Fields in Managing Glioblastoma: Guide for Oncologists.
Burri SH; Gondi V; Brown PD; Mehta MP
Am J Clin Oncol; 2018 Feb; 41(2):191-196. PubMed ID: 28832384
[TBL] [Abstract][Full Text] [Related]
6. Tumor treating fields therapy is feasible and safe in a 3-year-old patient with diffuse midline glioma H3K27M - a case report.
Gött H; Kiez S; Dohmen H; Kolodziej M; Stein M
Childs Nerv Syst; 2022 Sep; 38(9):1791-1796. PubMed ID: 35181800
[TBL] [Abstract][Full Text] [Related]
7. Tumor treating fields with radiation for glioblastoma: a narrative review.
Miller R; Niazi M; Russial O; Poiset S; Shi W
Chin Clin Oncol; 2022 Oct; 11(5):40. PubMed ID: 36336899
[TBL] [Abstract][Full Text] [Related]
8. Tumor treating fields for newly diagnosed high-grade glioma based on the criteria of 2021 WHO CNS5: A retrospective analysis of Chinese patients in a single center.
Zhang L; Ren Y; Peng Y; Luo Y; Liu Y; Wang X; Yang Y; Liu L; Ai P; Yang X; Li Y; Mao Q; Wang F
Cancer Med; 2024 Jun; 13(11):e7350. PubMed ID: 38859683
[TBL] [Abstract][Full Text] [Related]
9. Tumor-treating fields plus chemotherapy versus chemotherapy alone for glioblastoma at first recurrence: a post hoc analysis of the EF-14 trial.
Kesari S; Ram Z;
CNS Oncol; 2017 Jul; 6(3):185-193. PubMed ID: 28399638
[TBL] [Abstract][Full Text] [Related]
10. Global post-marketing safety surveillance of Tumor Treating Fields (TTFields) in patients with high-grade glioma in clinical practice.
Shi W; Blumenthal DT; Oberheim Bush NA; Kebir S; Lukas RV; Muragaki Y; Zhu JJ; Glas M
J Neurooncol; 2020 Jul; 148(3):489-500. PubMed ID: 32535723
[TBL] [Abstract][Full Text] [Related]
11. Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial.
Stupp R; Taillibert S; Kanner AA; Kesari S; Steinberg DM; Toms SA; Taylor LP; Lieberman F; Silvani A; Fink KL; Barnett GH; Zhu JJ; Henson JW; Engelhard HH; Chen TC; Tran DD; Sroubek J; Tran ND; Hottinger AF; Landolfi J; Desai R; Caroli M; Kew Y; Honnorat J; Idbaih A; Kirson ED; Weinberg U; Palti Y; Hegi ME; Ram Z
JAMA; 2015 Dec; 314(23):2535-43. PubMed ID: 26670971
[TBL] [Abstract][Full Text] [Related]
12. Bevacizumab for Patients with Recurrent Gliomas Presenting with a Gliomatosis Cerebri Growth Pattern.
Burger MC; Mildenberger IC; Wagner M; Mittelbronn M; Steinbach JP; Bähr O
Int J Mol Sci; 2017 Mar; 18(4):. PubMed ID: 28353668
[TBL] [Abstract][Full Text] [Related]
13. Effect of Tumor-Treating Fields Plus Maintenance Temozolomide vs Maintenance Temozolomide Alone on Survival in Patients With Glioblastoma: A Randomized Clinical Trial.
Stupp R; Taillibert S; Kanner A; Read W; Steinberg D; Lhermitte B; Toms S; Idbaih A; Ahluwalia MS; Fink K; Di Meco F; Lieberman F; Zhu JJ; Stragliotto G; Tran D; Brem S; Hottinger A; Kirson ED; Lavy-Shahaf G; Weinberg U; Kim CY; Paek SH; Nicholas G; Bruna J; Hirte H; Weller M; Palti Y; Hegi ME; Ram Z
JAMA; 2017 Dec; 318(23):2306-2316. PubMed ID: 29260225
[TBL] [Abstract][Full Text] [Related]
14. Tumor treating fields plus temozolomide for newly diagnosed glioblastoma: a sub-group analysis of Korean patients in the EF-14 phase 3 trial.
Kim CY; Paek SH; Nam DH; Chang JH; Hong YK; Kim JH; Kim OL; Kim SH
J Neurooncol; 2020 Feb; 146(3):399-406. PubMed ID: 32020470
[TBL] [Abstract][Full Text] [Related]
15. TTFields Prolonged the PFS of Epithelioid Glioblastoma Patient: A Case Report.
Ding Y; Wang Q; Wang F; Wu N; Li J; He X; Pan H; Wang L
Brain Sci; 2023 Apr; 13(4):. PubMed ID: 37190598
[TBL] [Abstract][Full Text] [Related]
16. Progress and prospect in tumor treating fields treatment of glioblastoma.
Liu S; Shi W; Zhao Q; Zheng Z; Liu Z; Meng L; Dong L; Jiang X
Biomed Pharmacother; 2021 Sep; 141():111810. PubMed ID: 34214730
[TBL] [Abstract][Full Text] [Related]
17. Planning TTFields treatment using the NovoTAL system-clinical case series beyond the use of MRI contrast enhancement.
Connelly J; Hormigo A; Mohilie N; Hu J; Chaudhry A; Blondin N
BMC Cancer; 2016 Nov; 16(1):842. PubMed ID: 27809808
[TBL] [Abstract][Full Text] [Related]
18. Tumor treating fields: a new standard treatment for glioblastoma?
Taillibert S; Le Rhun E; Chamberlain MC
Curr Opin Neurol; 2015 Dec; 28(6):659-64. PubMed ID: 26551239
[TBL] [Abstract][Full Text] [Related]
19. The effect of field strength on glioblastoma multiforme response in patients treated with the NovoTTF™-100A system.
Turner SG; Gergel T; Wu H; Lacroix M; Toms SA
World J Surg Oncol; 2014 May; 12():162. PubMed ID: 24884522
[TBL] [Abstract][Full Text] [Related]
20. [Glioblastoma multiforme developing separately from the initial lesion 9 years after successful treatment for gliomatosis cerebri: a case report].
Inoue T; Kanamori M; Sonoda Y; Watanabe M; Sasajima T; Kamisato N; Kumabe T; Tominaga T
No Shinkei Geka; 2008 Aug; 36(8):709-15. PubMed ID: 18700534
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
